Thymosin alpha-1

ID: thymosin_alpha1

Aliases: Ta1, Zadaxin, THYMOSIN ALPHA-1

Type: compound

Route/form: subcutaneous injection in labelled/regional use

Status: approved_in_some_countries

Evidence level: human RCT

Best data tier: human controlled/review; exact-use indirect

Support scope: human

Source types: human_rct, human_rct_negative

Linked sources: 3

Broad outcomes: Gut / immune / inflammation

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• immune modulation
• T-cell function

Optimization domains

• immune
• infection
• oncology adjunct

Research basis

• Human randomized trials exist in serious immune/infectious-disease contexts, with immune-parameter and clinical-endpoint signals.
• Useful as a contrast against purely preclinical peptides.

Limits, risks, and missing evidence

• Indications and regulatory status vary by country, and disease-context trials do not validate generic immune-optimization use.
• A large 2025 phase 3 sepsis RCT found no clear evidence of reduced 28-day all-cause mortality in adults with sepsis.
• Wellness-stack use often ignores immune phenotype and endpoint selection.

Risk flags

• immune modulation
• medical supervision
• disease context human data

Linked papers, labels, and reviews

1. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients
   human_rct / pubmed_thymosin_alpha1_pancreatitis_rct_2010
   Double-blind randomized pilot trial with immune parameters and infection outcomes.
2. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter randomized controlled trial
   human_rct / pmc_thymosin_alpha1_sepsis_etass_2014
   Multicenter severe sepsis RCT; useful for immune-modulation evidence and limitations.
3. The efficacy and safety of thymosin alpha 1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
   human_rct_negative / bmj_thymosin_alpha1_tests_sepsis_2025
   Large phase 3 sepsis RCT; found no clear evidence that thymosin alpha 1 decreased 28-day all-cause mortality in adults with sepsis.